After Hours Summary: WWE +10.5% jumps as Vince McMahon plans his return, will push for strategic alternatives; AEHR +15.5% higher on earnings; USNA -1.1% lower on guidanceAfter Hours Gainers:
Companies trading higher in after hours in reaction to earnings/guidance: AEHR +15.5%, SRTS +8.2%, DCT +2.5%, RCM +2.4%
Companies trading higher in after hours in reaction to news: CTMX +61.5% (CTMX announces collaboration and licensing agreement with MRNA), EFTR +17.8% (provides data update for Zotatifin and general corporate update), WWE +10.5% (Vince McMahon expects to return as exec chairman; will participate in upcoming media rights negotiations; also will push for review of strategic alternatives), FUSN +7% (FUSN and BWXT enter into supply agreement for actinium-225), CACI +4.4% (wins $2.25 bln Defense contract), TPIC +4.3% (extends supply agreements with GE Renewable Energy), DRS +3.8% (awarded U.S. Army contract), COST +2.8% (reports Dec sales), TDOC +1.4% (launches new app enabling whole-person care), LTC +1.4% (announces investment in 12 assisted living/memory care properties), MRNA +0.3% (CTMX announces collaboration and licensing agreement with MRNA), CHPT +0.2% (announces plans to rapidly expand 400 charging hubs), ASR +0.2% (reports December traffic), IPSC +0.2% (announces internal portfolio prioritization), SPWR +0.1% (SPWR and MAXN extend supply relationship)
After Hours Losers:
Companies trading lower in after hours in reaction to earnings/guidance: KRUS -4.9%, USNA -1.1%, PCRX -0.1%
Companies trading lower in after hours in reaction to news: FATE -49.5% (terminates collaboration agreement with Janssen), GRPH -42.8% (voluntary pause of Phase 1/2 CEDAR study), BBBY -7.1% (preparing to file for bankruptcy within weeks, according to WSJ), WKME -2.2% (names new Chairperson), LGIH -1.5% (closed 504 homes in Dec), ENVX -1.3% (delivers custom sample cells for US Army), MSA -0.1% (divests subsidiary holding legacy product liability claims), BWXT -0.1% (FUSN and BWXT enter into supply agreement for actinium-225), PFE -0.1% (may pull back on early-stage rare disease research, sell some major assets, according to Barron's)